Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) have been given a consensus recommendation of “Buy” by the seven ratings firms that are presently covering the company, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have updated their coverage […]
More Stories
Kyndryl (NYSE:KD) & Veea (NASDAQ:VEEA) Head-To-Head Survey
Kyndryl (NYSE:KD – Get Free Report) and Veea (NASDAQ:VEEA – Get Free Report) are both business services companies, but which...
Rubrik, Inc. (NYSE:RBRK) Receives $64.11 Consensus PT from Analysts
Rubrik, Inc. (NYSE:RBRK – Get Free Report) has received an average recommendation of “Buy” from the twenty analysts that are...
Head to Head Comparison: American Lithium (OTCMKTS:LIACF) vs. U.S. Gold (NASDAQ:USAU)
U.S. Gold (NASDAQ:USAU – Get Free Report) and American Lithium (OTCMKTS:LIACF – Get Free Report) are both small-cap basic materials...
Insider Selling: Intuit Inc. (NASDAQ:INTU) CEO Sells $47,257,500.00 in Stock
Intuit Inc. (NASDAQ:INTU – Get Free Report) CEO Sasan K. Goodarzi sold 75,000 shares of the business’s stock in a...
Caesars Entertainment (NASDAQ:CZR) Price Target Lowered to $43.00 at Jefferies Financial Group
Caesars Entertainment (NASDAQ:CZR – Get Free Report) had its price target reduced by analysts at Jefferies Financial Group from $52.00...
Insider Selling: Boot Barn Holdings, Inc. (NYSE:BOOT) CEO Sells 6,311 Shares of Stock
Boot Barn Holdings, Inc. (NYSE:BOOT – Get Free Report) CEO John Hazen sold 6,311 shares of the stock in a...